ASCO GU 2023: Rucaparib Extends Survival for Metastatic, Castration-Resistant Prostate Cancer
Findings seen compared with docetaxel or second-generation androgen-receptor pathway inhibitor
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.